Intuitive Surgical Is Jumping 2.7% Ahead of Earnings. Is the Robotics Stock Ready to Recover?

Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) reports Q1 2026 results on April 21 after the bell. However, is stock is rising 2.7% today. Yet, with the stock down 16.92% year-to-date and trading well below its post-Q4 price, this is a quarter where execution has to speak louder than narrative.

A Strong 2025 That the Market Has Already Discounted

Intuitive Surgical closed out 2025 in impressive fashion. Q4 revenue came in at $2.866B, beating estimates by 4.14% and growing 18.76% year over year. Non-GAAP EPS of $2.53 topped the $2.26 consensus by nearly 12%. Full-year 2025 marked a milestone: revenue crossed $10B for the first time, reaching $10.06B with non-GAAP EPS of $8.93.

Despite those results, the stock fell after the Q4 report. Shares closed at $523.99 the day of the release and drifted to $492.10 30 days later, while SPY gained 0.57% over the same period. The market’s reaction reflected a simple concern: 2026 guidance called for procedure growth of 13% to 15%, a meaningful step down from 18% in 2025. That deceleration, layered on top of tariff uncertainty, has weighed on sentiment all year.

CEO David Rosa framed the da Vinci 5 trajectory positively on the Q4 call. “Demand for da Vinci 5 strengthened throughout the year with customers responding to broader availability as we scaled manufacturing and increasing capability through subsequent software and product releases.” The system placed 870 times in 2025 globally, including 303 in Q4 alone, with over 10,000 surgeons using da Vinci 5 across more than 1,232 installed systems.

Consensus Estimates for Q1 2026

Note: Q1 2026 and full-year 2026 consensus estimates reflect analyst projections based on company guidance. Revenue and EPS estimates are not company-provided figures.

Tariffs, Margins, and the da Vinci 5 Ramp Are What Matter Now

Three metrics will be critical when the report hits Tuesday evening.

First, gross margin. Management guided non-GAAP gross margin of 67% to 68% for 2026, with tariffs accounting for roughly 1.2% of revenue as a headwind. That tariff estimate was built on conditions that have since shifted. Intuitive manufactures instruments and accessories in Mexico, endoscopes in Germany, and sources certain materials from China. Management flagged that additional tariffs could materially impact results. Q1 will be the first real read on whether that 1.2% estimate holds or worsens.

Second, da Vinci 5 placements. The sequential ramp through 2025 was striking: 147 in Q1 2025, 180 in Q2, 240 in Q3, and 303 in Q4. Q1 is historically a softer capital quarter for hospital systems. Placements holding above the Q1 2025 baseline or showing meaningful acceleration (particularly in international markets where da Vinci 5 launched in Europe and Japan only in the second half of 2025) will be a key signal.

Third, procedure growth. The 13% to 15% full-year guide implies moderation, but the shape matters. Management cited risks including changes to ACA premium subsidies, Medicaid funding pressures, capital challenges in Japan, and competitive intensity in China. A Q1 print at the high end of that range would meaningfully change the tone heading into the rest of the year. How management frames the cardiac surgery opportunity also warrants attention. The FDA cleared several cardiac procedures on da Vinci 5 in January, with an addressable market estimated at approximately 160,000 procedures annually. That is a long-term driver, but any update on early rollout progress matters.

Ion system momentum is worth a separate look. Ion procedure growth hit 44% in Q4 2025, with the installed base reaching 995 systems, up 24% year over year. Crossing 1,000 systems in Q1 would be a symbolic and practical milestone for recurring revenue contribution.

The Stock Needs a Reason to Recover

Intuitive Surgical has beaten earnings in all four quarters of 2025, yet the stock trades nearly 13% below its Q4 print of $538.30 and sits at $472.06 today. The analyst consensus price target is $591.51, implying meaningful upside, but sentiment will not shift on beats alone. This quarter, investors need clarity on tariff exposure and confirmation that procedure growth is tracking toward the upper end of guidance. A clean Q1 with stable margins and a credible tone on 2026 would likely shift the narrative heading into the rest of the year.